• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

    2/13/24 5:13:58 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLMD alert in real time by email
    SC 13G/A 1 tv01806-relmadatherapeuticsi.htm SCHEDULE 13G/A relmadatherapeuticsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Relmada Therapeutics Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  75955J402

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  75955J402

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    0

    7.  SOLE DISPOSITIVE POWER

    1,300,353

    8.  SHARED DISPOSITIVE POWER

    10,452

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,310,805

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.35%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Relmada Therapeutics Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    2222 Ponce de Leon Boulevard, 3rd floor
    Coral Gables, FL 33134

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    75955J402

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $RLMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLMD

    DatePrice TargetRatingAnalyst
    12/5/2024$23.00 → $1.00Outperform → Neutral
    Mizuho
    9/17/2024$3.50 → $13.00Hold → Buy
    Jefferies
    6/5/2024$3.00 → $2.00Neutral → Sell
    Goldman
    10/14/2022$81.00 → $8.00Buy → Neutral
    Goldman
    10/14/2022$90.00 → $10.00Buy → Hold
    Truist
    10/14/2022Buy → Neutral
    Guggenheim
    10/13/2022$64.00 → $7.00Outperform → Perform
    Oppenheimer
    12/20/2021$50.00 → $42.00Outperform
    SVB Leerink
    More analyst ratings

    $RLMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Kelly Paul Edward bought $198,000 worth of shares (90,000 units at $2.20), increasing direct ownership by 22% to 502,295 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    11/6/25 7:30:02 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Traversa Sergio bought $599,500 worth of shares (272,500 units at $2.20), increasing direct ownership by 27% to 1,272,500 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    11/6/25 7:30:04 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CAO and COO Ence Chuck bought $299,200 worth of shares (136,000 units at $2.20), increasing direct ownership by 51% to 403,931 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    11/6/25 7:30:05 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Relmada Therapeutics downgraded by Mizuho with a new price target

    Mizuho downgraded Relmada Therapeutics from Outperform to Neutral and set a new price target of $1.00 from $23.00 previously

    12/5/24 8:17:30 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics upgraded by Jefferies with a new price target

    Jefferies upgraded Relmada Therapeutics from Hold to Buy and set a new price target of $13.00 from $3.50 previously

    9/17/24 7:49:37 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics downgraded by Goldman with a new price target

    Goldman downgraded Relmada Therapeutics from Neutral to Sell and set a new price target of $2.00 from $3.00 previously

    6/5/24 7:16:28 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

    CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress. Conference Call and Webcast Information: Date: Thursday, November 13, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Webcast Access: Click Here A replay of the webcast will b

    11/7/25 7:30:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

    CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the pricing of its underwritten offering of 40,142,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,315,000 shares of common stock. The shares of common stock are being sold at an offering price of $2.20 per share, and the pre-funded warrants are being sold at an offering price of $2.199 per pre-funded warrant, which represents the per share offering price fo

    11/4/25 7:09:53 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

    Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized controlled trial in intermediate-risk NMIBC. FDA Feedback also confirms no additional non-clinical studies are required. 9-month follow-up for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and

    11/4/25 7:01:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Kelly Paul Edward bought $198,000 worth of shares (90,000 units at $2.20), increasing direct ownership by 22% to 502,295 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    11/6/25 7:30:02 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Traversa Sergio bought $599,500 worth of shares (272,500 units at $2.20), increasing direct ownership by 27% to 1,272,500 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    11/6/25 7:30:04 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CAO and COO Ence Chuck bought $299,200 worth of shares (136,000 units at $2.20), increasing direct ownership by 51% to 403,931 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    11/6/25 7:30:05 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    SEC Filings

    View All

    SEC Form 424B5 filed by Relmada Therapeutics Inc.

    424B5 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

    11/4/25 9:24:21 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

    11/4/25 9:25:57 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Relmada Therapeutics Inc.

    FWP - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    11/4/25 8:30:19 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Leadership Updates

    Live Leadership Updates

    View All

    Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

    Dr. Kates' experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Max Kates, MD, Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine, to Relmada's Clinical Advisory Board (CAB) to support the development of NDV-01 for the

    10/7/25 7:30:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

    Dr. Lotan's distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada's NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Yair Lotan, MD, a distinguished urologic oncologist, as Chair of Relmada's Clinical Advisory Board (CAB). Dr. Lotan's deep expertise in bladder cancer care and clinical research will be invaluable as Relmada prepa

    7/15/25 8:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

    SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Sergio Traversa, PharmD, as an Independent Director to its Board of Directors, effective June 25, 2025. Dr. Traversa currently serves as CEO of Relmada Therapeutics (NASDAQ:RLMD), a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions, where he has led the company through the advancement of multiple clinical-stage programs and financing events. "We're excited to welcome Sergio to the DIMERx team," said Nikhi

    7/9/25 8:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Financials

    Live finance-specific insights

    View All

    Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

    CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress. Conference Call and Webcast Information: Date: Thursday, November 13, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Webcast Access: Click Here A replay of the webcast will b

    11/7/25 7:30:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

    6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at 9 and 12 month data follow-up. Preparations underway to start Phase III registration trial in 1H 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in 1H 2026 Conference Call and Webcast Today at 4:30 PM ET CORAL GABLES, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous

    8/7/25 4:05:00 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress. Conference Call and Webcast Information: Date: Thursday, August 7, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13754263Webcast Access: Click Here A replay of the webc

    7/31/25 7:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Relmada Therapeutics Inc.

    SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    11/14/24 9:41:31 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

    SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    3/6/24 4:15:42 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

    SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    2/14/24 8:53:47 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care